Quantitative Multi-Parametric Magnetic Resonance Imaging of Tumor Response to Photodynamic Therapy

Objective The aim of this study was to characterize response to photodynamic therapy (PDT) in a mouse cancer model using a multi-parametric quantitative MRI protocol and to identify MR parameters as potential biomarkers for early assessment of treatment outcome. Methods CT26.WT colon carcinoma tumors were grown subcutaneously in the hind limb of BALB/c mice. Therapy consisted of intravenous injection of the photosensitizer Bremachlorin, followed by 10 min laser illumination (200 mW/cm2) of the tumor 6 h post injection. MRI at 7 T was performed at baseline, directly after PDT, as well as at 24 h, and 72 h. Tumor relaxation time constants (T1 and T2) and apparent diffusion coefficient (ADC) were quantified at each time point. Additionally, Gd-DOTA dynamic contrast-enhanced (DCE) MRI was performed to estimate transfer constants (Ktrans) and volume fractions of the extravascular extracellular space (ve) using standard Tofts-Kermode tracer kinetic modeling. At the end of the experiment, tumor viability was characterized by histology using NADH-diaphorase staining. Results The therapy induced extensive cell death in the tumor and resulted in significant reduction in tumor growth, as compared to untreated controls. Tumor T1 and T2 relaxation times remained unchanged up to 24 h, but decreased at 72 h after treatment. Tumor ADC values significantly increased at 24 h and 72 h. DCE-MRI derived tracer kinetic parameters displayed an early response to the treatment. Directly after PDT complete vascular shutdown was observed in large parts of the tumors and reduced uptake (decreased Ktrans) in remaining tumor tissue. At 24 h, contrast uptake in most tumors was essentially absent. Out of 5 animals that were monitored for 2 weeks after treatment, 3 had tumor recurrence, in locations that showed strong contrast uptake at 72 h. Conclusion DCE-MRI is an effective tool for visualization of vascular effects directly after PDT. Endogenous contrast parameters T1, T2, and ADC, measured at 24 to 72 h after PDT, are also potential biomarkers for evaluation of therapy outcome.

[1]  Klaas Nicolay,et al.  MRI methods for the evaluation of high intensity focused ultrasound tumor treatment: Current status and future needs , 2016, Magnetic resonance in medicine.

[2]  M. Schabel,et al.  Cluster analysis of DCE‐MRI data identifies regional tracer‐kinetic changes after tumor treatment with high intensity focused ultrasound , 2015, NMR in biomedicine.

[3]  Thomas E. Yankeelov,et al.  Quantitative multimodality imaging in cancer research and therapy , 2014, Nature Reviews Clinical Oncology.

[4]  G. Cron,et al.  Erratum to Dynamic contrast‐enhanced MRI in mice at high field: Estimation of the arterial input function can be achieved by phase imaging (Magn Reson Med 2014;71:544–550) , 2014 .

[5]  Klaas Nicolay,et al.  Multiparametric MRI Analysis for the Identification of High Intensity Focused Ultrasound-Treated Tumor Tissue , 2014, PloS one.

[6]  G. Cron,et al.  Dynamic contrast‐enhanced MRI in mice at high field: Estimation of the arterial input function can be achieved by phase imaging , 2014, Magnetic resonance in medicine.

[7]  Michael R Hamblin,et al.  Cell Death Pathways in Photodynamic Therapy of Cancer , 2011, Cancers.

[8]  Michael R Hamblin,et al.  Photodynamic therapy of cancer: An update , 2011, CA: a cancer journal for clinicians.

[9]  Baowei Fei,et al.  Diffusion‐weighted MRI for monitoring tumor response to photodynamic therapy , 2010, Journal of magnetic resonance imaging : JMRI.

[10]  T. Patrice,et al.  In vitro and in vivo evaluation of Radachlorin® sensitizer for photodynamic therapy , 2009, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[11]  W. Ahn,et al.  Photodynamic therapy with recombinant adenovirus AdmIL‐12 enhances anti‐tumour therapy efficacy in human papillomavirus 16 (E6/E7) infected tumour model , 2008, Immunology.

[12]  Baowei Fei,et al.  High‐field magnetic resonance imaging of the response of human prostate cancer to Pc 4‐based photodynamic therapy in an animal model , 2007, Lasers in surgery and medicine.

[13]  B. Ross,et al.  Diffusion magnetic resonance imaging: a biomarker for treatment response in oncology. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  P. Tofts,et al.  Fast, accurate, and precise mapping of the RF field in vivo using the 180° signal null , 2007, Magnetic resonance in medicine.

[15]  Robert A Weersink,et al.  Prostate gland: MR imaging appearance after vascular targeted photodynamic therapy with palladium-bacteriopheophorbide. , 2007, Radiology.

[16]  D. Collins,et al.  Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.

[17]  Nancy L. Oleinick,et al.  In vivo small animal imaging for early assessment of therapeutic efficacy of photodynamic therapy for prostate cancer , 2007, SPIE Medical Imaging.

[18]  M. Pearle,et al.  Time course of nicotinamide adenine dinucleotide diaphorase staining after renal radiofrequency ablation influences viability assessment. , 2007, Journal of endourology.

[19]  B. Wilson,et al.  Magnetic resonance imaging correlated with the histopathological effect of Pd‐bacteriopheophorbide (Tookad) photodynamic therapy on the normal canine prostate gland , 2006, Lasers in surgery and medicine.

[20]  P. Wolf,et al.  Comparison of topical methyl aminolevulinate photodynamic therapy with cryotherapy or Fluorouracil for treatment of squamous cell carcinoma in situ: Results of a multicenter randomized trial. , 2006, Archives of dermatology.

[21]  Bergein F Overholt,et al.  Photodynamic therapy with porfimer sodium for ablation of high-grade dysplasia in Barrett's esophagus: international, partially blinded, randomized phase III trial. , 2005, Gastrointestinal endoscopy.

[22]  M. Biel,et al.  mTHPC‐mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients , 2004, Head & neck.

[23]  B. Krammer,et al.  Vascular effects of photodynamic therapy. , 2001, Anticancer research.

[24]  A. Scherz,et al.  Antivascular Treatment of Solid Melanoma Tumors with Bacteriochlorophyll–serine‐based Photodynamic Therapy ¶ , 2001, Photochemistry and photobiology.

[25]  H. Grondey,et al.  Magnetic Resonance Imaging Evaluation of Photodynamic Therapy‐Induced Hemorrhagic Necrosis in the Murine M1 Tumor Model , 1997, Photochemistry and photobiology.

[26]  V. Fingar,et al.  Vascular effects of photodynamic therapy. , 1996, Journal of clinical laser medicine & surgery.

[27]  T. Foster,et al.  Quantitative MRI of Gd‐DTPA uptake in tumors: Response to photo dynamic therapy , 1994, Magnetic resonance in medicine.

[28]  R Deichmann,et al.  Quantification of T1 values by SNAPSHOT-FLASH NMR imaging , 1992 .

[29]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[30]  J. Moore,et al.  In vivo magnetic resonance imaging of the effects of photodynamic therapy. , 1989, British Journal of Cancer.

[31]  Ray Freeman,et al.  Compensation for Pulse Imperfections in NMR Spin-Echo Experiments , 1981 .

[32]  J. Vácha Blood volume in inbred strain BALB/c, CBA/J and C57BL/10 mice determined by means of 59Fe-labelled red cells and 59Fe bound to transferrin. , 1975, Physiologia Bohemoslovaca.

[33]  T J Dougherty,et al.  Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. , 1975, Journal of the National Cancer Institute.

[34]  M. Port,et al.  Comparative Relaxivities and Efficacies of Gadolinium-based Commercial Contrast Agents , 2012 .

[35]  R. Hawk,et al.  In vivo relaxation time measurements on a murine tumor model--prolongation of T1 after photodynamic therapy. , 1995, Magnetic resonance imaging.